Navigation Links
Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
Date:3/5/2008

LOS ANGELES, March 5 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.52 price target on Inovio Biomedical Corporation (Amex: INO). "Inovio has compelling pre-clinical and clinical data regarding the ability of their technology to significantly enhance the potency of DNA vaccines, with positive interim human results from three independent clinical studies. The company's technology is further validated from license agreements with two of the world's big five vaccine companies, Merck and Wyeth, plus multiple other partnerships and collaborations," said Ross Silver, Director of Research for Vista Partners. For more information and to download the report, please visit the Vista Partners website at http://www.vistap.com.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Inovio Biomedical Corporation:

Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based immunotherapies. Inovio is a leader in developing human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Interim human data has shown that Inovio's DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at http://www.inovio.com.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Provista Awards Agreement to Spheris
5. Synvista Therapeutics to be Featured on Wallst.net
6. Synvista Therapeutics to Present at the BIO InvestorForum 2007
7. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
8. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
9. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
10. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
11. DW Healthcare Partners Announces the Sale of Tandem Labs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... Research and Markets has announced the addition ... to their offering. ... The study scope includes ... chassis organisms, synthetic cells, production systems), enabling technologies (DNA ... specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... 16, 2017 UCHealth ( Aurora, Colorado ... for pulmonary nodule patient management. In addition to optimizing ... spot on the lung, UCHealth looks to improve provider ... entry. Stephanie Brown, RN , Thoracic ... patients with an Excel spreadsheet, which was extremely arduous ...
Breaking Biology Technology:
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, a ... emerging technology, announces the availability of a new report, Sensors ... Continue Reading ... ... and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets ...
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
(Date:1/23/2017)... 23, 2017  The latest mobile market research from ... dropped dramatically. The quarterly average price of a biometric ... in Q4 2016.  There are now 120 sub-$150 models ... up from just 28 a year ago at an ... Maxine Most , Acuity Market Intelligence Principal, "Biometric ...
Breaking Biology News(10 mins):